Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback